Ever wondered what happens to your manuscript after submission? In this episode, the JHEP Reports editorial team takes you behind the scenes: from first triage to reviewer selection, smart moves vs. red flags, and how final decisions are made. The discussion also explores the potential, limitations, and ethical pitfalls.

Moderator: Mattias Mandorfer 

Speakers: Tobias Böttler, Virginia Hernández-Gea, Josep Llovet

All EASL Studio Podcasts are available on EASL Campus.

Click here to see all EASL Video Podcasts on Apple Podcasts.

After years of limited progress, recent trials hint at a changing landscape for primary sclerosing cholangitis (PSC). In this episode, experts review emerging data and explore whether we’re approaching a new era of effective treatment. How should clinicians assess these therapies, and could they shift the current management of PSC?

Moderator: Debbie Shawcross

Speakers: Cynthia Levy, Stephen Rossi, Michael Trauner

All EASL Studio Podcasts are available on EASL Campus.

Click here to see all EASL Video Podcasts on Apple Podcasts.

Listen to this EASL Studio episode to explore how artificial intelligence (AI) is transforming healthcare. Discuss its potential to revolutionise medical practice, its limitations, and whether it poses a threat or an opportunity for the future of the medical profession.

Moderator: Ahmed Elsharkawy  

Faculty: Jakob Kather, Sabela Lens, Ashley Spann 

Related episodes:

• EASL Studio at EASL Congress 2024 – Exploring new frontiers: The AI liver taskforce initiative
• S4E5 – AI for dummies
• S2E13 – Digital Pathology

All EASL Studio Podcasts are available on EASL Campus.

Click here to see all EASL Video Podcasts on Apple Podcasts.

Machine perfusion is changing the status quo in liver transplantation by optimising the use of organs in times of organ shortage.

Watch this EASL Studio to:

• Better understand the role of machine perfusion in liver transplantation
• Understand the optimal situations in machine perfusion is beneficial
• Have an overview of the different types of machines under evaluation

Faculty

• Prof. Marina Berenguer (Moderator)
• Prof. Pierre-Alain Clavien (Faculty)
• Dr Amelia Hessheimer (Faculty)

Related episodes

• S3E8 – Transplanting patients with cancer – Is there a limit?
• S3E2 – Liver transplantation for ACLF: Opportunities, challenges, and pitfalls

All EASL Studio Podcasts are available on EASL Campus.

The field of artificial Intelligence (AI) is rapidly growing and derived technologies are technologies are increasingly being used in medical sciences to improve patient outcomes.

• What exactly is AI?
• How can it be beneficial?
• Why should AI be used in medicine?

Watch this EASL Studio to find out.

Faculty

• Prof. Jakob Nikolas Kather (Moderator)
• Prof. Julien Calderaro (Faculty)
• Dr Arsela Prelaj (Faculty)
• Dr Tobias Seraphin (Faculty)
• Dr Katy Wack (Faculty)

All EASL Studio Podcasts are available on EASL Campus.

Although there is an almost unanimous consensus on the prognostic weight of the term ‘decompensation’, a clear corresponding consensus on its definition is still lacking. In addition, classifying cirrhosis as compensated and decompensated oversimplifies the clinical course of the disease which encompasses many different groups.

Faculty

• Prof. Paolo Angeli (Moderator)
• Prof. Guadalupe Garcia-Tsao (Faculty)
• Prof. Salvatore Piano (Faculty)
• Prof. Thomas Reiberger (Faculty)

All EASL Studio Podcasts are available on EASL Campus.

Alcohol is the main cause of advanced liver disease and a major cause of hospitalisation and disability across the globe, including Europe. In this EASL Studio you will hear the patient perspective from an individual who has overcome this disease and listen to the faculty discuss the measures that can help prevent it.

Faculty

• Prof. Ramon Bataller (Moderator)
• Prof. Giovanni Addolorato (Faculty)
• Prof. Peter Jepsen (Faculty)
• Prof. Debbie Shawcross (Faculty)
• Mrs Kristen Radage (Faculty)
• Mr. Steven Rodrigues (Patient Perspective)

Related episodes

• S3E5: JHEP Live: Stigma and alcohol
• S3E4: Special Edition: Highlights of EASL NAFLD Summit 2022

All EASL Studio Podcasts are available on EASL Campus.

The value of scientific collaboration and data sharing through registries and consortia is unequivocal. But what are the main challenges to building a consortium and how do we overcome them.

Join the faculty as they provide you with a practical, experience-based view of how to build a successful consortium.

Faculty

• Dr Marta Afonso (Moderator)
• Dr Mattias Mandorfer (Moderator)
• Prof. Jesús Bañales (Faculty)
• Prof. Rajiv Jalan (Faculty)
• Prof. Pierre Emmanuel Rautou (Faculty)

All EASL Studio Podcasts are available on EASL Campus.

In the first episode of EASL Studio season 4, the faculty looked at the current status of hepatitis B elimination and discussed what needs to be done to achieve it.

Faculty

• Dr Ahmed Elsharkawy (Moderator)
• Mr Danjuma K. Adda (Faculty)
• Prof. Maud Lemoine (Faculty)
• Prof. Jean-Michel Pawlotsky (Faculty)
• Dr John Ward (Faculty)

Related episodes

• Special Edition: Live from Viral Hepatitis Elimination Conference 2022
• S3E2: Interview with Stephan Urban – From bench to bedside: Process of developing the first HBV/HDV entry inhibitor
• S2E8: Treatment of HBV-HDV coinfection in the era of entry inhibition

All EASL Studio Podcasts are available on EASL Campus.

Results from current clinical trials are rapidly evolving, with mixed results. In this EASL Studio the faculty discuss:

• why certain trials have failed whereas others have succeeded,
• what we have learned about the connection between overall survival and progression-free survival as endpoints, and
• how the systemic therapy of HCC has evolved.

Faculty

• Prof. Peter Galle (Moderator)
• Prof. Bruno Sangro (Faculty)
• Dr Anna Saborowski (Faculty)
• Prof. Arndt Vogel (Faculty)

Related episodes

• S2E15 – JHEP Live – The best animal model for HCC — lost in translation
• Special Edition: Highlights of the Liver Cancer Summit 2022
• Policy Dialogues Episode 3: Liver Cancer: The risk of ignorance

All EASL Studio Podcasts are available on EASL Campus.

In this episode of EASL Studio the experts discuss a non-cirrhotic portal vein thrombosis (PVT):

• What is PVT in the absence of cirrhosis,
• The role of interventional radiology in the management of portal cavernoma, and
• An update from the VALDIG portal Vein Thrombosis meeting

Faculty

• Prof. Pierre-Emmanuel Rautou (Moderator)
• Prof. Juan-Carlos Garcia-Pagan (Faculty)
• Dr Aurélie Plessier (Faculty)

All EASL Studio Podcasts are available on EASL Campus.

As we near the end of 2022, this EASL Studio reflects upon:

• Which topics were most published about
• Which fields will we focus on in 2023
• What will the future of hepatology look like?

Faculty

• Prof. Paolo Angeli (Moderator)
• Prof. Jessica Zucman-Rossi (Moderator)
• Prof. Thomas Berg (Faculty)
• Prof. Aleksander Krag (Faculty)

All EASL Studio Podcasts are available on EASL Campus.

Traditionally, journal impact factor has been the way to measure the impact of ones scientific articles. However, social media platforms are increasingly being used for the dissemination of publications. Join the faculty as they debate novel metrics to measure the impact of articles.

Faculty

• Prof. Jesus Banales (Moderator)
• Dr Atoosa Rabiee (Faculty)
• Dr Elliot Tapper (Faculty)
• Dr Juan Turnes (Faculty)

Related episode

• New era for science dissemination: The role of social media

All EASL Studio Podcasts are available on EASL Campus.

With the release of the new HBV guidelines, treatment eligibility broadens. This EASL Studio explores how to communicate these changes, support shared decision-making, ensure adherence, and engage patients in ongoing care and clinical trials.

Moderator: Ahmed Elsharkawy 

Faculty: Markus Cornberg, Sital Shah, Thomas Tu, Su Wang

This EASL Studio is supported by Aligos Therapeutics, GSK and Gilead Sciences Europe Ltd . EASL has received no input from Aligos Therapeutics, GSK or Gilead Sciences Europe Ltd with regards to the content of this programme.

All EASL Studio Podcasts are available on EASL Campus.

Click here to see all EASL Video Podcasts on Apple Podcasts.

Antimicrobial resistance (AMR) is growing problem that greatly impacts treatment outcome. In this episode the faculty discuss:

• The impact of prescribing antibiotics as primary and secondary prophylaxis on AMR rates
• What can be done globally to reduce AMR rates

Faculty

• Prof. Debbie Shawcross (Moderator)
• Prof. Jonel Trebicka (Moderator)
• Prof. Jasmohan Bajaj (Faculty)
• Dr Lindsey Edwards (Faculty)
• Dr Benedikt Huttner (Faculty, WHO representative)

All EASL Studio Podcasts are available on EASL Campus.

Currently, the only established therapeutic option for end-stage liver disease is orthotopic liver transplantation. However, the paucity of donor organs limits this option to only a few patients. From liver stem cells to advanced tissue bioengineering, this episode of EASL Studio discusses regenerative hepatology techniques as an alternative treatment for patients.

Faculty

• Prof. Pedro Baptista (Moderator)
• Prof. Tobias Cantz (Faculty)
• Prof. Karen Piper Hanley (Faculty)
• Prof. Frederic Lemaigre (Faculty)

Related episode:

• YI Choice: Propelling liver cell biology into the third dimension

All EASL Studio Podcasts are available on EASL Campus.

In this JHEP Live the faculty discuss the use of antisense oligonucleotides and siRNAs in the treatment of chronic hepatitis B infections.

Faculty

• Prof. Joerg Petersen (Moderator)
• Prof. Maria Buti (Faculty)
• Prof. Man-Fung Yuen (Faculty)

All EASL Studio Podcasts are available on EASL Campus.

Listen to this EASL Studio to find out:

• Which policies for prioritisation exist within a deceased donor liver allocation system?
• What is the impact of novel cancer therapies on the selection of patients with prior cancer?

Faculty

• Prof. Sherrie Bhoori (Moderator)
• Prof. Pål-Dag Line (Faculty)
• Prof. Vincenzo Mazzaferro (Faculty)
• Prof. Gonzalo Sapisochin (Faculty)

All EASL Studio Podcasts are available on EASL Campus.

In recent years, the role of the gut microbiome in the development and severity of various diseases has come to light. In this episode, the experts examines:

• The role of microbiome in obesity.
• The role of microbiome in the transition from NAFLD to NASH.
• Practical solutions in microbiome medications.

Faculty

• Prof. Oren Shibolet (Moderator)
• Dr Aleksandra Kolodziejczyk (Faculty)
• Prof. Eran Elinav (Faculty)

All EASL Studio Podcasts are available on EASL Campus.

In honour of World Hospice and Palliative Care Day (8 October), this EASL Studio episode examines:

• When is the best time to think about end-of-life care in liver disease?
• What does it mean for the liver care team?
• When and how should patients be referred to specialised palliative care?

Faculty

• Dr Patrizia Künzler-Heule (Moderator)
• Prof. Philip Larkin (Faculty)
• Dr Philip Berry (Faculty)

All EASL Studio Podcasts are available on EASL Campus.

People suffering from alcohol-related liver (ALD) disorders are subject to several forms of stigma. If not addressed, stigma may lead towards unfavourable health outcomes. This JHEP Live – based on a recent review – discusses:

• What forms of stigma do people suffering from ALD face?
• How does stigma affect them?
• What can be done about it?

ℹ️ Read this article for more information: G. Schomerus et al. The stigma of alcohol-related liver disease and its impact on healthcare Journal of Hepatology 2022 vol. 77 : 516–524

Faculty

• Prof. Patrizia Burra (Moderator)
• Prof. Georg Schomerus (Moderator)
• Dr Patrizia Carrieri (Faculty)
• Prof. Philippe Mathurin (Faculty)

All EASL Studio Podcasts are available on EASL Campus.

This episode of EASL Studio discusses the latest data in the treatment of NAFLD presented at the EASL NAFLD Summit 2022.

Faculty

• Prof. Amalia Gastaldelli (Faculty)
• Prof. Frank Tacke (Faculty)
• Prof. Emmanuel Tsochatzis (Faculty)

All EASL Studio Podcasts are available on EASL Campus.

This EASL Studio discusses important issues related to the opportunities and challenges of liver transplantation in acute-on-chronic liver failure (ACLF).

• Does urgent liver transplantation improve the survival of patients with ACLF-3 and where are the limits?
• Are the current allocation systems adequate and how to implement ACLF criteria for prioritisation?
• The distinct lack of equity of access of ACLF-3 patients to liver transplantation: Where are the barriers?
• What data will the CHANCE study deliver to address some of the unanswered questions?

Faculty

• Prof. Rajiv Jalan (Moderator)
• Dr Thierry Artzner (Faculty)
• Prof. Luca Belli (Faculty)
• Prof. Marina Berenguer (Faculty)

Patient perspective

• Dr Amit Verma (United Kingdom)
• Dr Devangi Verma (United Kingdom)

All EASL Studio Podcasts are available on EASL Campus.

 Several recent reports have postulated a link between autoimmune hepatitis (AIH) following SARS-CoV-2 infection or vaccination. This EASL Studio JHEP Live discuss the potential links between COVID-19 and AIH.

Faculty

• Prof. Vlad Ratziu (Moderator)
• Prof. Naga Chalasani (Moderator)
• Prof. Fernando Bril (Faculty)
• Prof. Robert Fontana (Faculty)
• Dr Johannes Hartl (Faculty)

ℹ️ More information on the topic can be found in these articles:

• Autoimmune hepatitis and COVID-19: No increased risk for AIH after vaccination but reduced care, Rüther et al., J Hepatol. 2022 Jul; 77(1): 250–251
• SARS-CoV-2 vaccination can elicit a CD8 T-cell dominant hepatitis, Böttler et al., J Hepatol. 2022 Apr 21

All EASL Studio Podcasts are available on EASL Campus.

Listen to this EASL Studio episode for insights on the new MASLD guidelines and their practical application. Hear from experts on navigating the nomenclature change, implementing guidelines in clinical workflows, and fostering behavioral change to improve patient outcomes across the care team.

Moderator: Sven Francque 

Faculty: Marta Cervera, Elena George, Shelley Keating

This programme is part of the EASL Guidelines Implementation Programme on MASLD supported by Boehringer Ingelheim and Madrigal Pharmaceuticals. Boehringer Ingelheim or Madrigal Pharmaceuticals have had no input in the selection and creation of this programme.

Related episode

• S5E5 – JHEP Live: The new nomenclature for SLD: A multidisciplinary evaluation and approach

All EASL Studio Podcasts are available on EASL Campus.

Click here to see all EASL Video Podcasts on Apple Podcasts.

This is the audio version of an episode that was originally broadcast live from The International Liver Congress 2022.

Discover all the EASL Studio episodes at ILC 2022 here.

This is the audio version of an episode that was originally broadcast live from The International Liver Congress 2022.

Discover all the EASL Studio episodes at ILC 2022 here.

This is the audio version of an episode that was originally broadcast live from The International Liver Congress 2022.

Discover all the EASL Studio episodes at ILC 2022 here.

This is the audio version of an episode that was originally broadcast live from The International Liver Congress 2022.

Discover all the EASL Studio episodes at ILC 2022 here.

This is the audio version of an episode that was originally broadcast live from The International Liver Congress 2022.

Discover all the EASL Studio episodes at ILC 2022 here.

Issues of climate change, global warming and sustainability are taking centre stage in political agendas across the globe, causing major restructuring in many sectors. But, what about the healthcare sector?

• How is climate change affecting healthcare?
• How big of a problem is climate change for liver care?
• What public health strategies can be implemented to mitigate the effects of climate change?

You can find more information about the impact of climate change on liver disease care in this publication.

Related podcast episodes: 

EASL Studio Podcast S2E12: Nurse and AHP Focus: Sustainable Hepatology – Insights in nursing initiatives

All EASL Studio Podcasts are available on EASL Campus.

In honour of World Haemochromatosis week (1-7 June 2022) the newly updated EASL Clinical Practice Guidelines on Haemochromatosis will be discussed in this episode of EASL Studio.

Read more

All EASL Studio Podcasts are available on EASL Campus.

Mouse models, based on dietary, chemical or genetic interventions, are designed to serve as tools to understand human liver diseases.

With the number of models increasing:

• What types of models exist for hepatocellular carcinoma?
• How close do they mirror human liver cancer (subtypes)?
• Can they be used to predict therapeutic response?
• What are the best models? For which questions?
• From idea to conception, are we getting lost in translation?

Read this recent Journal of Hepatology article, on which the discussion was based.

Read more

All EASL Studio Podcasts are available on EASL Campus.

In the assessment of disease stage, liver pathology is still largely based on semi-quantitative methods. Recent advances in whole slide imaging have opened the door for the use of artificial intelligence (AI) and the creation of machine learning (ML) algorithms.

• What exactly is digital pathology?
• How can it be implemented in different disease areas?
• Can it be used in routine clinical practice?

Read more

All EASL Studio Podcasts are available on EASL Campus.

In honour of the International Nurse Day (12 May), and to discuss sustainability in liver care, this week we will gain some insights into the impact of nursing initiatives.

• What is sustainable liver care?
• What role do nurses currently play?
• What current nurse-driven activities are promoting a sustainable clinical practice?

Read more

All EASL Studio Podcasts are available on EASL Campus.

Listen to this episode for a curated overview of landmark studies and breakthrough data presented at EASL Congress 2025, with expert insights on their clinical relevance and impact on the future of hepatology.

Moderator: Thomas Berg 

Faculty: Hannes Hagström, Verena Keitel, Raj Mookerjee

All EASL Studio Podcasts are available on EASL Campus.

Click here to see all EASL Video Podcasts on Apple Podcasts.

Reduce, Refine, Replace. Developed over 50 years ago, the 3Rs provide a framework that urges researchers to think carefully about methods used to investigate scientific questions. In this episode of EASL Studio, we took a closer look at the third R, Replace. With the World Day for Laboratory Animals fast approaching, we discussed how to propel liver cell biology into the third dimension.

• What are the advantages of 3D cultures?
• Can liver cell types be studied in representative manner using 3D cultures?
• More importantly, which part of animal research can be replaced by 3D cell culture experiments?

This and more in EASL Studio: YI Choice.

Read more

All EASL Studio Podcasts are available on EASL Campus.

Discover this EASL Studio Podcast highlighting the recently published EASL Clinical Practice Guidelines on prevention and management of bleeding and thrombosis in patients with cirrhosis. Join the faculty as they discuss:

• What effects do anticoagulants have on survival and liver related events in cirrhosis?
• What are the mechanisms of action?
• What type of anticoagulants should be used in patients with cirrhosis?

Read more

All EASL Studio Podcasts are available on EASL Campus.

In recent years social media has become a powerful tool, not only for science dissemination, but also for discussing data and networking.

• What is the impact of dissemination via social media?
• How is social media changing the way data is communicated?
• Should social media activity be considered a professional endeavour?

Listen to this podcast to find out.

Read more

All EASL Studio Podcasts are available on EASL Campus.

Discover this EASL Studio podcast discussing the Baveno Consensus started over 30 years ago with the aim of reviewing current diagnostic and therapeutic strategies and producing updated definitions.

But, with the extension of indication of non-selective beta blockers, has the consensus gone too far?

• Is there enough evidence for their use in already decompensated patients?
• How safe are they in this patient population?
• What do we know about the effects on refractory ascites? Circulatory dysfunction?

Read more

All EASL Studio Podcasts are available on EASL Campus.

In this podcast conducted on the occasion of liver cancer awareness month, Dr. Massimo A. Iavarone, hepatologist at the Ospedale Maggiore in Milan, Italy, is answering key questions on liver cancer raised by the Liver Patients International (LPI) and PSC Support, two EASL-affiliated patient associations, both part of the EASL patient synergies project.

Most liver diseases are diagnosed when it’s already too late. This episode explores the pros and cons of early screening, the gaps in current strategies, and how projects like LIVERAiM are aiming to change the game.

Moderator: Ahmed Elsharkawy

Faculty: Pere Ginès, Ian Rowe, Maja Thiele

All EASL Studio Podcasts are available on EASL Campus.

Click here to see all EASL Video Podcasts on Apple Podcasts.

This EASL Studio episode cuts through the noise to explore alcohol’s true impact on health and society, spotlighting patient stories, public misconceptions, and bold policy solutions from across Europe.

Moderator: David Barret (Internal Communications and Multimedia Manager, WHO Regional Office for Europe)

Faculty: Carina Ferreira-Borges (Regional Advisor for Alcohol, Illicit drugs and Prison health, WHO Regional Office for Europe), Aleksander Krag (EASL Secretary General), Hazel Martin (BBC Journalist and Liver Patient), Margarida Santos (General Practitioner Portugal), Riina Sikkut (Member of Estonian Parliament, former Minister of Health of Estonia)

All EASL Studio Podcasts are available on EASL Campus.

Click here to see all EASL Video Podcasts on Apple Podcasts.

What happens when hepatologists and interventional radiologists join forces? This episode discusses the power of collaboration – shared guidelines, joint training, and multidisciplinary care – to improve outcomes in complex liver disease.

Moderator: Sven Francque

Faculty: Irene Bargellini, Virginia Hernández-Gea, Max Seidensticker

All EASL Studio Podcasts are available on EASL Campus.

Click here to see all EASL Video Podcasts on Apple Podcasts.

In this fifth edition of the EASL DeepDive, join Christophe Bureau, Virginia Hernandez-Gea, Marika Rudler, and Manhal Izzy to gain expert insight into the selection, management, and outcomes of patients undergoing Transjugular Intrahepatic Portosystemic Shunt (TIPS) procedures.

This EASL DeepDive webinar is supported by W. L. Gore & Associates. W. L. Gore & Associates has had no input into the content of this EASL DeepDive.

Learning objectives

• Understand the criteria for selecting appropriate patients for Transjugular Intrahepatic Portosystemic Shunt (TIPS) procedures
• Learn to differentiate between high-risk and low-risk patients based on clinical indicators and patient history
• Explore the impact of cardiopulmonary conditions on the outcomes of TIPS procedures, and how/when to monitor for new-onset heart failure post TIPS
• Learn from Marika Rudler about the strategies for preventing and managing post-TIPS hepatic encephalopathy (HE)
• Discuss the latest research and treatments available for managing EH in TIPS patients

All EASL DeepDive are available on EASL Campus.

This EASL Studio episode discusses cutting-edge approaches for managing bleeding varices. Explore the evolution of endoscopic therapies, the role of interventional radiology, and decision-making for high-risk gastric varices. Gain insights into EUS-guided portal pressure assessment and its impact on tailoring treatment strategies.

Moderator: Debbie Shawcross

Faculty: Wim Laleman, David Patch

Related episode

• S6E14: Endohepatology: The endoscopic liver gold rush

All EASL Studio Podcasts are available on EASL Campus.

Click here to see all EASL Video Podcasts on Apple Podcasts.

In this EASL DeepDive held on 06 November 2024, Alice Turner, Pavel Strnad, and Nicola Brunetti discuss and explore the changing insights in the management of Alpha-1 Antitrypsin Deficiency.

Learning objectives:

1. Learn more about the role of heterozygosity of alpha-1 as a risk factor for chronic liver disease, especially in the context of other causes such as MASLD or alcohol
2. Get a better understanding of the extrahepatic manifestations and the need for a multi-disciplinary approach
3. Learn more about screening: who to screen and how
4. Discover the general unmet needs related to AAT, with an emphasis on awareness and timely diagnosis

This EASL DeepDive webinar is supported by Takeda Pharmaceuticals. Takeda Pharmaceuticals has had no input into the content of this EASL DeepDive.

Click here to see all EASL Video Podcasts on Apple Podcasts.

This episode questions whether assigning the label “ACLF” to a deteriorating patient truly alters clinical decisions, or if focusing on the specifics of organ failure and reversibility is more useful. Experts debate the real-world utility of prognostic scores, the clarity (or confusion) created by multiple definitions, and whether the ACLF concept drives urgency, facilitates transplant access, or improves outcomes. A thought-provoking look at where terminology meets bedside care.

Moderator: Tom Marjot 

Speakers: Paolo Angeli and Julia Wendon

This EASL Studio is supported by GENFIT. EASL has received no input from GENFIT with regards to the content of this programme. 

All EASL Studio Podcasts are available on EASL Campus.

Click here to see all EASL Video Podcasts on Apple Podcasts.

In this EASL DeepDive held on 03 July 2024, Palak Trivedi, Emma Culver, Andreas Kremer and Jessica Dyson explain the risk assessment in people with PBC as well as the mechanistic and treatment of fatigue and pruritus.

Learning objectives

• Discover the latest mechanistic insights relating to the occurrence of PBC symptoms
• Learn more about the holistic management of PBC symptoms, with a particular emphasis on fatigue and pruritus
• Learn more about the current treatment options, their efficacy and limitations
• Get a detailed understanding of the drugs in the pipeline for the near future

This EASL DeepDive webinar is supported by GSK and IPSEN. GSK and IPSEN have had no input into the content of this EASL DeepDive.

Click here to see all EASL Video Podcasts on Apple Podcasts.

In this EASL DeepDive held on 30 October 2024, Henning Grønbæk, Cyrielle Caussy, Mazen Noureddin and Frank Tacke provide an understanding of the role of glucagon and glucagon-receptors in physiology and in MASH patients. Additionally, they review key clinical trials and evaluate the integration of GLP-1 receptor agonists into current EASL-EASD-EASO clinical guidelines for practical patient management.

Learning objectives:

1. Understand the role of glucagon and glucagon-receptor in normal physiology and disease.
2. Understand the rationale of a combined dual GLP-1/GCG RA and its potential benefit compared to a GLP-1RA alone and thus gain insights into the mechanisms through which GLP-1 receptor agonists and GLP-1/GCG might affect liver pathology and metabolic regulation.
3. Discuss and review key clinical trials and ongoing development programs.
4. Evaluate how GLP-1RA can be integrated into current EASL-EASD-EASO CPGs, with a focus on practical applications and patient management strategies, giving potential guidance for future applications.

This EASL DeepDive webinar is supported by Boehringer Ingelheim. Boehringer Ingelheim has had no input into the content of this EASL DeepDive.

Click here to see all EASL Video Podcasts on Apple Podcasts.